Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
NCT ID: NCT05546879
Last Updated: 2024-09-19
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
52 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-03-15
Study Completion Date
2027-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in first line setting in patients with unresectable hepatocellular carcinoma.The study drug which is tested is the NP137 in association with Atezolizumab-Bevacizumab to allow a better tumor response as well as better survival outcomes with an acceptable safety.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or
NCT04730388
Advanced Hepatocellular Carcinoma
UNKNOWN
Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
NCT05448677
Hepatocellular Carcinoma
TERMINATED
PHASE2
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
NCT07018947
Resectable Hepatocellular Carcinoma
NOT_YET_RECRUITING
PHASE2
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
NCT05337137
Carcinoma, Hepatocellular
COMPLETED
PHASE1/PHASE2
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
NCT06138769
Hepatocellular Carcinoma
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is a multicentric, prospective, single arm phase 1b trial. This study will enroll 43 to 52 patients and consists of 2 parts: Safety Lead-in Phase and Expansion Phase. Initially, 3 to 12 patients will be enrolled into a Safety Lead-in Phase based on a 3 + 3 design, with the possibility of dose de-escalation, to confirm the recommended dose of NP137 .The Expansion Phase will start after completion of Safety Lead-in Phase at the confirmed dose and will include 40 patients. Patients will be assigned to the experimental single arm (NP137+ Atezolizumab-Bevacizumab).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hepatocellular Carcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Multicentric prospective single arm phase 1b trial
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
NP137+Atezolizumab-Bevacizumab
Group Type
EXPERIMENTAL
NP137
Intervention Type
DRUG
NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
Atezolizumab
Intervention Type
DRUG
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
Bevacizumab
Intervention Type
DRUG
Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NP137
NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
Intervention Type
DRUG
Atezolizumab
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
Intervention Type
DRUG
Bevacizumab
Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Males or females ≥ 18 years of age
2. Histologically confirmed (liver biopsy within 24 previous weeks) and documented unresectable hepatocellular carcinoma
3. Patients with a BCLC C or BCLC B status ineligible for or in failure of locoregional treatment, as per the Barcelona Clinic Liver Cancer (BCLC) staging system
4. No prior systemic therapy for advanced HCC
5. Liver tumor burden \< 50% of the liver (per Investigator judgment)
6. Child-Pugh A (≤ 6) without any history of cirrhotic decompensation within the past 6 months
7. Antiviral therapy required in hepatitis B virus patients (Hepatitis B antigen positive)
8. Willing to have liver biopsy between C4 and C5
9. Presence of a measurable tumor per RECIST v1.1 criteria
10. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
11. Life expectancy ≥ 12 weeks
12. Absence of previous liver decompensation
13. In case of cirrhosis, last esophageal varices detection by esogastroduodenal endoscopy have to be performed within last the 6 months before inclusion
14. Adequate hematologic function prior to the first dose of NP137, defined as:
Absolute neutrophils count ≥ 1500 cells/μL 14.2. Hemoglobin ≥ 9 g/dL with no transfusion within 4 weeks prior to first planned dose of NP137 14.3. Platelet count \> 50,000/μL with no transfusion within 2 weeks prior to first planned dose of NP137
15. Adequate renal function prior to first dose, defined as:
15.1. Serum creatinine \< 1.5 × Upper limit of normal (ULN ) 15.2. Creatinine clearance ≥ 30 mL/min/m2 (by Cockroft-Gault equation of 24-hour urine) if creatinine ≥ 1.5 × ULN
16. Adequate hepatic function prior first dose, defined as AST/ALT ≤ 5 × ULN
17. Women patients of childbearing potential must have a negative serum pregnancy test at screening and baseline, and be willing to use a highly effective contraception. The patient should be advised to continue the contraception for at least 6 months following the completion of dosing. Women with cessation for \> 24 months of previously occurring menses, or women of any age who have had a hysterectomy, or have had both ovaries removed will be considered to be of non-childbearing potential.
18. Male patients of reproductive potential must be willing to use one acceptable method of contraception, as judged by Investigator and Sponsor and/or to refrain from donating sperm from the time of screening through at least 6 months following the completion of dose administration.
19. Amenable to computed tomography (CT) with 3 or 4 phase liver or magnetic resonance imaging (MRI) of abdomen and pelvis, and CT of chest, or MRI of whole body, for initial tumor size measurements and subsequent follow-up.
20. Absence of other clinically relevant abnormalities for any screening laboratory test results as judged by the Investigator and Sponsor.
21. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
22. Able to understand and provide written informed consent
23. Patients covered by Health Insurance System
2. Histologically confirmed (liver biopsy within 24 previous weeks) and documented unresectable hepatocellular carcinoma
3. Patients with a BCLC C or BCLC B status ineligible for or in failure of locoregional treatment, as per the Barcelona Clinic Liver Cancer (BCLC) staging system
4. No prior systemic therapy for advanced HCC
5. Liver tumor burden \< 50% of the liver (per Investigator judgment)
6. Child-Pugh A (≤ 6) without any history of cirrhotic decompensation within the past 6 months
7. Antiviral therapy required in hepatitis B virus patients (Hepatitis B antigen positive)
8. Willing to have liver biopsy between C4 and C5
9. Presence of a measurable tumor per RECIST v1.1 criteria
10. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
11. Life expectancy ≥ 12 weeks
12. Absence of previous liver decompensation
13. In case of cirrhosis, last esophageal varices detection by esogastroduodenal endoscopy have to be performed within last the 6 months before inclusion
14. Adequate hematologic function prior to the first dose of NP137, defined as:
Absolute neutrophils count ≥ 1500 cells/μL 14.2. Hemoglobin ≥ 9 g/dL with no transfusion within 4 weeks prior to first planned dose of NP137 14.3. Platelet count \> 50,000/μL with no transfusion within 2 weeks prior to first planned dose of NP137
15. Adequate renal function prior to first dose, defined as:
15.1. Serum creatinine \< 1.5 × Upper limit of normal (ULN ) 15.2. Creatinine clearance ≥ 30 mL/min/m2 (by Cockroft-Gault equation of 24-hour urine) if creatinine ≥ 1.5 × ULN
16. Adequate hepatic function prior first dose, defined as AST/ALT ≤ 5 × ULN
17. Women patients of childbearing potential must have a negative serum pregnancy test at screening and baseline, and be willing to use a highly effective contraception. The patient should be advised to continue the contraception for at least 6 months following the completion of dosing. Women with cessation for \> 24 months of previously occurring menses, or women of any age who have had a hysterectomy, or have had both ovaries removed will be considered to be of non-childbearing potential.
18. Male patients of reproductive potential must be willing to use one acceptable method of contraception, as judged by Investigator and Sponsor and/or to refrain from donating sperm from the time of screening through at least 6 months following the completion of dose administration.
19. Amenable to computed tomography (CT) with 3 or 4 phase liver or magnetic resonance imaging (MRI) of abdomen and pelvis, and CT of chest, or MRI of whole body, for initial tumor size measurements and subsequent follow-up.
20. Absence of other clinically relevant abnormalities for any screening laboratory test results as judged by the Investigator and Sponsor.
21. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
22. Able to understand and provide written informed consent
23. Patients covered by Health Insurance System
Exclusion Criteria
1. Any known history of encephalopathy within 6 months prior to first planned dose of treatment
2. Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding
3. Known esophageal varices with recent history of bleeding (within previous 6 months)
4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
5. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
6. Chronic treatment with immunosuppressive agents (like steroids) ≤ 6 weeks prior to first planned dose of treatment.
7. Major surgical procedures, open biopsy or significant traumatic injury ≤ 4 weeks prior to first dose of treatment or anticipation of major surgical procedure during the course of the trial, minor surgical procedures ≤ 1 week of first planned dose (the surgical wound must be fully healed)
8. Local therapy to liver within 28 days prior to initiation of study treatment or non-recovery from side effects of any such procedure
9. Any clinically significant cardiovascular condition as judged by the Investigator (such as New York Heart Association Class II or greater cardiac failure, myocardial infarction, or cerebrovascular accident within 3 months prior to Day 1 of Cycle 1, uncontrolled arterial hypertension, unstable arrhythmia, or unstable angina)
10. Severe or uncontrolled renal condition
11. Untreated chronic hepatitis B
12. Co-infection of HBV and HCV
13. Use of any prohibited concomitant medications within 14 days of the Baseline/Day 1 visit
14. Contraindication to additionnal liver biopsy planned between C4 and C5
15. Contraindication to iodinated contrast agent infusion
16. Known current alcohol (\> 20g/ Day in women and \> 30g/ Day in men) or substance abuse
17. History of leptomeningeal disease
18. Active or history of autoimmune disease or immune deficiency
19. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
20. Known active tuberculosis
21. History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
22. Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 6 months after the last dose of treatment
23. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
24. Uncontrolled tumor-related pain
25. Uncontrolled or symptomatic hypercalcemia
26. Treatment with systemic immunostimulatory agents
27. Inadequately controlled arterial hypertension
28. Prior history of hypertensive crisis or hypertensive encephalopathy
29. Evidence of bleeding diathesis or significant coagulopathy
30. History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration
31. Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
32. Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses
33. Known clinically significant or life threatening organ or systemic disease such that in the opinion of the Investigator, the significance of the disease will compromise the patient\'s participation in the trial
34. Known intolerance or hypersensitivity to the active ingredient or to one of the components of the study drug
35. Persistent toxicities related to prior treatment of grade greater than 1
36. Subjects with active infection
37. History of bone marrow allograft or solid organ transplant
38. Subjects requiring corticosteroid therapy at a dose equivalent to more than 10 mg of prednisone equivalent dose per day (corticosteroid administration is permitted by a route resulting in minimal systemic exposure \[cutaneous, rectal, articular, ocular or inhalation\] is authorized).
39. Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies
40. History of gastrointestinal perforations and fistulae
41. Uncontrolled or symptomatic proteinuria
42. Active aneurysm considered as unstable and/or at high risk of complication
43. Patients who experienced immune-mediated pericardial disorders during previous treatment by immune checkpoint blockade therapies, including anti-CTLA4, anti-PD1, and anti-PDL1 therapeutic antibodies
44. Subject who participate or plan to participate in another interventional clinical trial or who is in exclusion period for another study,
45. Subject who cannot be contacted in case of emergency
46. Persons referred to in Articles L1121-5 to L1121-8 of the French code of public health (this corresponds to all persons protected: pregnant or parturient women, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure).
2. Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding
3. Known esophageal varices with recent history of bleeding (within previous 6 months)
4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
5. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
6. Chronic treatment with immunosuppressive agents (like steroids) ≤ 6 weeks prior to first planned dose of treatment.
7. Major surgical procedures, open biopsy or significant traumatic injury ≤ 4 weeks prior to first dose of treatment or anticipation of major surgical procedure during the course of the trial, minor surgical procedures ≤ 1 week of first planned dose (the surgical wound must be fully healed)
8. Local therapy to liver within 28 days prior to initiation of study treatment or non-recovery from side effects of any such procedure
9. Any clinically significant cardiovascular condition as judged by the Investigator (such as New York Heart Association Class II or greater cardiac failure, myocardial infarction, or cerebrovascular accident within 3 months prior to Day 1 of Cycle 1, uncontrolled arterial hypertension, unstable arrhythmia, or unstable angina)
10. Severe or uncontrolled renal condition
11. Untreated chronic hepatitis B
12. Co-infection of HBV and HCV
13. Use of any prohibited concomitant medications within 14 days of the Baseline/Day 1 visit
14. Contraindication to additionnal liver biopsy planned between C4 and C5
15. Contraindication to iodinated contrast agent infusion
16. Known current alcohol (\> 20g/ Day in women and \> 30g/ Day in men) or substance abuse
17. History of leptomeningeal disease
18. Active or history of autoimmune disease or immune deficiency
19. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
20. Known active tuberculosis
21. History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
22. Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 6 months after the last dose of treatment
23. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
24. Uncontrolled tumor-related pain
25. Uncontrolled or symptomatic hypercalcemia
26. Treatment with systemic immunostimulatory agents
27. Inadequately controlled arterial hypertension
28. Prior history of hypertensive crisis or hypertensive encephalopathy
29. Evidence of bleeding diathesis or significant coagulopathy
30. History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration
31. Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
32. Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses
33. Known clinically significant or life threatening organ or systemic disease such that in the opinion of the Investigator, the significance of the disease will compromise the patient\'s participation in the trial
34. Known intolerance or hypersensitivity to the active ingredient or to one of the components of the study drug
35. Persistent toxicities related to prior treatment of grade greater than 1
36. Subjects with active infection
37. History of bone marrow allograft or solid organ transplant
38. Subjects requiring corticosteroid therapy at a dose equivalent to more than 10 mg of prednisone equivalent dose per day (corticosteroid administration is permitted by a route resulting in minimal systemic exposure \[cutaneous, rectal, articular, ocular or inhalation\] is authorized).
39. Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies
40. History of gastrointestinal perforations and fistulae
41. Uncontrolled or symptomatic proteinuria
42. Active aneurysm considered as unstable and/or at high risk of complication
43. Patients who experienced immune-mediated pericardial disorders during previous treatment by immune checkpoint blockade therapies, including anti-CTLA4, anti-PD1, and anti-PDL1 therapeutic antibodies
44. Subject who participate or plan to participate in another interventional clinical trial or who is in exclusion period for another study,
45. Subject who cannot be contacted in case of emergency
46. Persons referred to in Articles L1121-5 to L1121-8 of the French code of public health (this corresponds to all persons protected: pregnant or parturient women, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure).
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NETRIS Pharma
INDUSTRY
Sponsor Role
collaborator
University Hospital, Grenoble
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gaël ROTH, MD PHD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Grenoble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de GRENOBLE ALPES
Grenoble, Alpes, France
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
France
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC22.210
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)
NCT06416683
COMPLETED
Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
NCT05665348
RECRUITING
PHASE2/PHASE3
Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
NCT05173298
RECRUITING
Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma
NCT06806579
RECRUITING
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
NCT05096715
RECRUITING
PHASE1
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
NCT04727307
RECRUITING
PHASE2
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
NCT04487067
COMPLETED
PHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791
ACTIVE_NOT_RECRUITING
PHASE3
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
NCT05263830
RECRUITING
Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy
NCT05197504
COMPLETED
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
NCT07009470
ACTIVE_NOT_RECRUITING
NA
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
NCT06796114
RECRUITING
NA
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
NCT04102098
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
NCT05211323
ACTIVE_NOT_RECRUITING
PHASE2
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
NCT00328770
COMPLETED
PHASE2/PHASE3
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159
RECRUITING
PHASE2
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
NCT04732286
TERMINATED
PHASE3
Ate-Bev Early Response Prediction Model in Advanced HCC
NCT05763277
RECRUITING
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
NCT06096779
RECRUITING
PHASE2
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785
RECRUITING
PHASE3
Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellular Carcinoma
NCT06086002
UNKNOWN
NA
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT03434379
COMPLETED
PHASE3
Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma
NCT05908916
NOT_YET_RECRUITING
PHASE2
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
NCT04180072
ACTIVE_NOT_RECRUITING
NA